8-K: Beyond Air Reports 45% Revenue Increase, Faces Nasdaq Delisting Notice

Beyond Air announced a 45% increase in quarterly revenue and the appointment of a new CEO for its NeuroNOS subsidiary, while also receiving a delisting notice from Nasdaq due to its stock price falling below $1.00.

Summary

• Beyond Air reported a 45% increase in revenue for the quarter ended June 30, 2024, compared to the previous quarter, reaching $0.7 million.
• The company's LungFit PH device has expanded its reach to over 55 hospitals across 10 states, with more than $5 million in contracted revenue through fiscal year 2027.
• Beyond Air received a notification from Nasdaq regarding its stock price falling below the minimum bid price of $1.00, giving them until February 4, 2025, to regain compliance.
• Amir Avniel was appointed CEO of NeuroNOS, the company's subsidiary focused on neurological disorders, and resigned from the board and as Chief Business Officer, effective August 15, 2024.
• The company is reiterating its revenue guidance of at least $10 million for fiscal year 2025 and expects net cash burn to be less than $30 million in the same period.
• The company's net loss for the quarter was $12.2 million, or a loss of $0.27 per share, compared to a net loss of $14.1 million, or a loss of $0.45 per share, for the same period last year.
• Cash burn for the quarter was $13.1 million, and the company had $21.4 million in cash, cash equivalents, and marketable securities as of June 30, 2024.
• The company has reduced its headcount by over 25% since January 1, 2024, as part of its capital conservation strategy.

Sentiment

Score: 4

Explanation: The document presents mixed signals. While there is positive revenue growth and commercial progress, the Nasdaq delisting notice, significant losses, and cash burn raise concerns. The sentiment is cautiously negative due to the financial challenges and delisting risk.

Positives

• The company experienced a significant 45% increase in quarterly revenue, indicating strong sales growth.
• The LungFit PH device is gaining traction, with usage in over 55 hospitals and more than $5 million in contracted revenue.
• The company is implementing a capital conservation strategy, including a 25% headcount reduction, to extend its cash runway.
• The company is reiterating its revenue guidance of at least $10 million for fiscal year 2025.
• The company expects to achieve cash flow breakeven in the fourth fiscal quarter of 2026.
• The company has a new Chief Commercial Officer, David Webster, who is expected to strengthen commercial strategy and execution.

Negatives

• The company received a delisting notice from Nasdaq due to its stock price falling below $1.00.
• The company reported a net loss of $12.2 million for the quarter.
• The cost of revenue exceeded revenue, primarily due to investments in supply chain infrastructure and depreciation of LungFit devices.
• The company's cash burn for the quarter was $13.1 million.
• The company's cash, cash equivalents, and marketable securities have decreased to $21.4 million.

Risks

• The company faces the risk of being delisted from Nasdaq if it cannot regain compliance with the minimum bid price requirement by February 4, 2025.
• There is no assurance that the company will be able to regain compliance with the minimum bid price requirement or other Nasdaq listing criteria.
• The company is experiencing significant losses and cash burn, which could impact its ability to fund operations.
• The company's cost of revenue currently exceeds its revenue, which could impact profitability.
• The company's success is dependent on the commercial success of its LungFit PH device and the development of its other product candidates.

Future Outlook

The company expects revenue to be greater than $10 million for fiscal year 2025 and net cash burn to be less than $30 million. They also anticipate achieving cash flow breakeven in the fourth fiscal quarter of 2026.

Management Comments

• Steve Lisi, Chairman and Chief Executive Officer of Beyond Air, stated that the team continues to enhance the commercial execution for LungFit PH and is confident in the long-term growth of the system.
• Steve Lisi also noted that the company is seeing an increasing number of customer engagements for multi-year contracts.
• The company highlighted that its capital conservation strategy has strengthened its cash runway to focus on LungFit PH's launch.

Industry Context

The company operates in the medical device and biopharmaceutical industry, focusing on nitric oxide therapies. The announcement highlights the commercial progress of their LungFit PH device, which competes with traditional cylinder-based nitric oxide systems. The company is also expanding into neurological disorders with its NeuroNOS subsidiary, which is a growing area of research and development.

Comparison to Industry Standards

• The 45% revenue increase quarter-over-quarter is a positive sign, but the company's overall revenue of $0.7 million is still relatively low compared to established medical device companies.
• The company's net loss of $12.2 million and cash burn of $13.1 million are significant and need to be addressed to achieve long-term sustainability.
• The company's LungFit PH device is competing with established nitric oxide delivery systems, such as those offered by Mallinckrodt, which has a much larger market share.
• The company's expansion into neurological disorders with NeuroNOS is a strategic move, but it is still in early stages of development compared to companies like Roche and Biogen that have established positions in the neurology space.
• The company's goal to achieve cash flow breakeven in the fourth fiscal quarter of 2026 is ambitious and will require significant revenue growth and cost management.

Management Changes

Stakeholder Impact

• Shareholders are negatively impacted by the Nasdaq delisting notice and the company's financial losses.
• Employees have been impacted by the 25% headcount reduction.
• Customers are benefiting from the increased availability of the LungFit PH device.
• The company's suppliers may be impacted by the company's capital conservation strategy.
• Creditors are exposed to the company's financial risks.

Next Steps

• The company intends to actively monitor the closing bid price of its common stock and evaluate options to regain compliance with Nasdaq listing requirements.
• The company plans to continue the commercial launch of LungFit PH and advance its other product candidates.
• The company will continue to implement its capital conservation strategy.
• The company expects a decision on the cardiac surgery PMA supplement for LungFit PH from the FDA before year-end 2024.
• The company expects a decision on CE Mark for LungFit PH in Europe before year-end 2024.
• The company anticipates submitting a PMA for a transport-ready LungFit PH to the FDA by year-end 2024 or early 2025.

Key Dates

Keywords

LungFit PH, Nitric Oxide, Nasdaq, Delisting, Revenue, NeuroNOS, Autism Spectrum Disorder, Capital Conservation, Medical Device, Biopharmaceutical